Which has higher earnings & valuation, BIIB or KRYS?

Biogen has higher revenue and earnings than Krystal Biotech. Biogen is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biogen $10.03B 3.19 $1.29B $5.65 38.37 Krystal Biotech $389.13M 26.36 $204.83M $7.98 43.43

Is BIIB or KRYS more profitable?

Krystal Biotech has a net margin of 54.82% compared to Biogen's net margin of 8.32%. Krystal Biotech's return on equity of 19.34% beat Biogen's return on equity. Company Net Margins Return on Equity Return on Assets Biogen 8.32% 11.18% 6.88% Krystal Biotech 54.82% 19.34% 17.65%

Does the media refer more to BIIB or KRYS?

In the previous week, Biogen had 20 more articles in the media than Krystal Biotech. MarketBeat recorded 28 mentions for Biogen and 8 mentions for Krystal Biotech. Biogen's average media sentiment score of 1.33 beat Krystal Biotech's score of 1.20 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 22 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Krystal Biotech 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to KRYS or ALNY?

In the previous week, Alnylam Pharmaceuticals had 19 more articles in the media than Krystal Biotech. MarketBeat recorded 27 mentions for Alnylam Pharmaceuticals and 8 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.20 beat Alnylam Pharmaceuticals' score of 0.78 indicating that Krystal Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 13 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, KRYS or INSM?

Krystal Biotech has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Krystal Biotech $389.13M 26.36 $204.83M $7.98 43.43 Insmed $606.42M 45.29 -$1.28B -$4.11 N/A

Is KRYS or INSM more profitable?

Krystal Biotech has a net margin of 54.82% compared to Insmed's net margin of -76.94%. Krystal Biotech's return on equity of 19.34% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Krystal Biotech 54.82% 19.34% 17.65% Insmed -76.94% -123.94% -44.30%

Does the media prefer KRYS or INSM?

In the previous week, Krystal Biotech had 7 more articles in the media than Insmed. MarketBeat recorded 8 mentions for Krystal Biotech and 1 mentions for Insmed. Insmed's average media sentiment score of 1.44 beat Krystal Biotech's score of 1.20 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, ROIV or KRYS?

Krystal Biotech has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Roivant Sciences $8.26M 3,174.36 -$299.77M -$0.53 N/A Krystal Biotech $389.13M 26.36 $204.83M $7.98 43.43

Does the media favor ROIV or KRYS?

In the previous week, Roivant Sciences had 11 more articles in the media than Krystal Biotech. MarketBeat recorded 19 mentions for Roivant Sciences and 8 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.20 beat Roivant Sciences' score of 0.48 indicating that Krystal Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Krystal Biotech 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is KRYS or MRNA more profitable?

Krystal Biotech has a net margin of 54.82% compared to Moderna's net margin of -141.43%. Krystal Biotech's return on equity of 19.34% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Krystal Biotech 54.82% 19.34% 17.65% Moderna -141.43% -28.30% -19.39%

Does the media prefer KRYS or MRNA?

In the previous week, Moderna had 105 more articles in the media than Krystal Biotech. MarketBeat recorded 113 mentions for Moderna and 8 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.20 beat Moderna's score of 0.40 indicating that Krystal Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 46 Very Positive mention(s) 16 Positive mention(s) 14 Neutral mention(s) 18 Negative mention(s) 14 Very Negative mention(s) Neutral

Krystal Biotech (KRYS) Competitors

$346.58 +9.56 (+2.84%)

As of 08/21/2026 04:00 PM Eastern

Compare

KRYS vs. BIIB, ALNY, INSM, ROIV, and MRNA

Should you buy Krystal Biotech stock or one of its competitors? Krystal Biotech's main competitors and comparable companies include Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Insmed (INSM), Roivant Sciences (ROIV), and Moderna (MRNA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Krystal Biotech compare to Biogen?

Biogen (NASDAQ:BIIB) and Krystal Biotech (NASDAQ:KRYS) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

87.9% of Biogen shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 0.3% of Biogen shares are owned by company insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Biogen has higher revenue and earnings than Krystal Biotech. Biogen is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$10.03B	3.19	$1.29B	$5.65	38.37
Krystal Biotech	$389.13M	26.36	$204.83M	$7.98	43.43

Krystal Biotech has a net margin of 54.82% compared to Biogen's net margin of 8.32%. Krystal Biotech's return on equity of 19.34% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
Krystal Biotech	54.82%	19.34%	17.65%

Biogen presently has a consensus target price of $227.07, indicating a potential upside of 4.75%. Krystal Biotech has a consensus target price of $365.40, indicating a potential upside of 5.43%. Given Krystal Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Krystal Biotech is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

Biogen has a beta of 0.17, indicating that its stock price is 83% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market.

In the previous week, Biogen had 20 more articles in the media than Krystal Biotech. MarketBeat recorded 28 mentions for Biogen and 8 mentions for Krystal Biotech. Biogen's average media sentiment score of 1.33 beat Krystal Biotech's score of 1.20 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	22 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Krystal Biotech	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Krystal Biotech beats Biogen on 10 of the 16 factors compared between the two stocks.

How does Krystal Biotech compare to Alnylam Pharmaceuticals?

Krystal Biotech (NASDAQ:KRYS) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Alnylam Pharmaceuticals has higher revenue and earnings than Krystal Biotech. Krystal Biotech is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	26.36	$204.83M	$7.98	43.43
Alnylam Pharmaceuticals	$4.80B	6.58	$313.75M	$5.38	43.91

In the previous week, Alnylam Pharmaceuticals had 19 more articles in the media than Krystal Biotech. MarketBeat recorded 27 mentions for Alnylam Pharmaceuticals and 8 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.20 beat Alnylam Pharmaceuticals' score of 0.78 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	13 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Krystal Biotech has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market.

Krystal Biotech currently has a consensus price target of $365.40, suggesting a potential upside of 5.43%. Alnylam Pharmaceuticals has a consensus price target of $386.62, suggesting a potential upside of 63.67%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	15 Buy rating(s)	4 Strong Buy rating(s)	2.96

Krystal Biotech has a net margin of 54.82% compared to Alnylam Pharmaceuticals' net margin of 15.26%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Krystal Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	54.82%	19.34%	17.65%
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%

Summary

Alnylam Pharmaceuticals beats Krystal Biotech on 10 of the 17 factors compared between the two stocks.

How does Krystal Biotech compare to Insmed?

Krystal Biotech (NASDAQ:KRYS) and Insmed (NASDAQ:INSM) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

86.3% of Krystal Biotech shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by insiders. Comparatively, 2.1% of Insmed shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Krystal Biotech has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market. Comparatively, Insmed has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market.

Krystal Biotech has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	26.36	$204.83M	$7.98	43.43
Insmed	$606.42M	45.29	-$1.28B	-$4.11	N/A

Krystal Biotech has a net margin of 54.82% compared to Insmed's net margin of -76.94%. Krystal Biotech's return on equity of 19.34% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	54.82%	19.34%	17.65%
Insmed	-76.94%	-123.94%	-44.30%

In the previous week, Krystal Biotech had 7 more articles in the media than Insmed. MarketBeat recorded 8 mentions for Krystal Biotech and 1 mentions for Insmed. Insmed's average media sentiment score of 1.44 beat Krystal Biotech's score of 1.20 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Krystal Biotech presently has a consensus price target of $365.40, suggesting a potential upside of 5.43%. Insmed has a consensus price target of $205.52, suggesting a potential upside of 63.41%. Given Insmed's stronger consensus rating and higher probable upside, analysts clearly believe Insmed is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Krystal Biotech beats Insmed on 9 of the 17 factors compared between the two stocks.

How does Krystal Biotech compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Krystal Biotech (NASDAQ:KRYS) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

Krystal Biotech has a net margin of 54.82% compared to Roivant Sciences' net margin of -3,534.96%. Krystal Biotech's return on equity of 19.34% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
Krystal Biotech	54.82%	19.34%	17.65%

Roivant Sciences presently has a consensus price target of $35.14, suggesting a potential downside of 3.21%. Krystal Biotech has a consensus price target of $365.40, suggesting a potential upside of 5.43%. Given Krystal Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Krystal Biotech is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 8.8% of Roivant Sciences shares are held by company insiders. Comparatively, 13.1% of Krystal Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Krystal Biotech has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,174.36	-$299.77M	-$0.53	N/A
Krystal Biotech	$389.13M	26.36	$204.83M	$7.98	43.43

In the previous week, Roivant Sciences had 11 more articles in the media than Krystal Biotech. MarketBeat recorded 19 mentions for Roivant Sciences and 8 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.20 beat Roivant Sciences' score of 0.48 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Krystal Biotech	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Roivant Sciences has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market.

Summary

Krystal Biotech beats Roivant Sciences on 13 of the 16 factors compared between the two stocks.

How does Krystal Biotech compare to Moderna?

Krystal Biotech (NASDAQ:KRYS) and Moderna (NASDAQ:MRNA) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Krystal Biotech has a net margin of 54.82% compared to Moderna's net margin of -141.43%. Krystal Biotech's return on equity of 19.34% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	54.82%	19.34%	17.65%
Moderna	-141.43%	-28.30%	-19.39%

In the previous week, Moderna had 105 more articles in the media than Krystal Biotech. MarketBeat recorded 113 mentions for Moderna and 8 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.20 beat Moderna's score of 0.40 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	46 Very Positive mention(s)	16 Positive mention(s)	14 Neutral mention(s)	18 Negative mention(s)	14 Very Negative mention(s)	Neutral

Krystal Biotech has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	26.36	$204.83M	$7.98	43.43
Moderna	$1.94B	29.79	-$2.82B	-$7.99	N/A

Krystal Biotech presently has a consensus price target of $365.40, indicating a potential upside of 5.43%. Moderna has a consensus price target of $69.50, indicating a potential downside of 52.09%. Given Krystal Biotech's stronger consensus rating and higher probable upside, research analysts clearly believe Krystal Biotech is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Moderna	4 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.00

Krystal Biotech has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market. Comparatively, Moderna has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market.

Summary

Krystal Biotech beats Moderna on 13 of the 17 factors compared between the two stocks.

Get Krystal Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KRYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KRYS vs. The Competition

Export

Metric	Krystal Biotech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$10.26B	$4.01B	$7.38B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	43.43	11.62	272.60	24.25
Price / Sales	26.36	1,334.62	623.33	101.53
Price / Cash	47.54	105.14	78.62	53.99
Price / Book	7.55	16.80	13.05	6.20
Net Income	$204.83M	-$12.50M	$3.47B	$348.59M
7 Day Performance	4.31%	3.29%	2.09%	0.08%
1 Month Performance	5.83%	8.23%	6.64%	3.88%
1 Year Performance	130.30%	55.05%	25.02%	16.98%

Krystal Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KRYS Krystal Biotech	4.1152 of 5 stars	$346.58 +2.8%	$365.40 +5.4%	+130.3%	$10.26B	$389.13M	43.43	210	Positive News Analyst Downgrade
BIIB Biogen	3.9575 of 5 stars	$209.15 -0.3%	$227.07 +8.6%	+55.6%	$31.00B	$9.89B	37.02	7,500	News Coverage Positive News
ALNY Alnylam Pharmaceuticals	4.9356 of 5 stars	$224.60 -1.8%	$393.86 +75.4%	-48.0%	$30.60B	$3.71B	41.75	2,770	News Coverage Analyst Upgrade
INSM Insmed	3.4485 of 5 stars	$128.32 +3.7%	$205.52 +60.2%	-4.6%	$27.02B	$606.42M	N/A	1,664	Positive News
ROIV Roivant Sciences	1.5306 of 5 stars	$36.24 +0.1%	$35.14 -3.0%	+204.5%	$26.15B	$8.26M	N/A	860	Positive News Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KRYS) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Krystal Biotech (KRYS) Competitors

KRYS vs. BIIB, ALNY, INSM, ROIV, and MRNA

How does Krystal Biotech compare to Biogen?

Summary

How does Krystal Biotech compare to Alnylam Pharmaceuticals?

Summary

How does Krystal Biotech compare to Insmed?

Summary

How does Krystal Biotech compare to Roivant Sciences?

Summary

How does Krystal Biotech compare to Moderna?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRYS vs. The Competition

Krystal Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Krystal Biotech (KRYS) Competitors

KRYS vs. BIIB, ALNY, INSM, ROIV, and MRNA

How does Krystal Biotech compare to Biogen?

Do insiders & institutionals have more ownership in BIIB or KRYS?

Which has higher earnings & valuation, BIIB or KRYS?

Is BIIB or KRYS more profitable?

Do analysts recommend BIIB or KRYS?

Which has more risk and volatility, BIIB or KRYS?

Does the media refer more to BIIB or KRYS?

Summary

How does Krystal Biotech compare to Alnylam Pharmaceuticals?

Which has higher earnings & valuation, KRYS or ALNY?

Does the media refer more to KRYS or ALNY?

Do insiders & institutionals believe in KRYS or ALNY?

Which has more risk and volatility, KRYS or ALNY?

Do analysts rate KRYS or ALNY?

Is KRYS or ALNY more profitable?

Summary

How does Krystal Biotech compare to Insmed?

Do insiders and institutionals hold more shares of KRYS or INSM?

Which has more risk and volatility, KRYS or INSM?

Which has better earnings and valuation, KRYS or INSM?

Is KRYS or INSM more profitable?

Does the media prefer KRYS or INSM?

Do analysts prefer KRYS or INSM?

Summary

How does Krystal Biotech compare to Roivant Sciences?

Is ROIV or KRYS more profitable?

Do analysts recommend ROIV or KRYS?

Do institutionals & insiders hold more shares of ROIV or KRYS?

Which has preferable valuation and earnings, ROIV or KRYS?

Does the media favor ROIV or KRYS?

Which has more risk & volatility, ROIV or KRYS?

Summary

How does Krystal Biotech compare to Moderna?

Do institutionals and insiders have more ownership in KRYS or MRNA?

Is KRYS or MRNA more profitable?

Does the media prefer KRYS or MRNA?

Which has higher valuation and earnings, KRYS or MRNA?

Do analysts prefer KRYS or MRNA?

Which has more risk and volatility, KRYS or MRNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRYS vs. The Competition

Krystal Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools